Evidence map›Paper›PMID 38884858›Full record

ArticleInfection2024

Accurate and affordable detection of rifampicin and isoniazid resistance in Tuberculosis sputum specimens by multiplex PCR-multiple probes melting analysis.

Long Xie, Xiao-Ya Zhu, Li Xu, Xiao-Xie Xu, Ze-Fan Ruan, Ming-Xiang Huang, Li Chen, Xi-Wen Jiang

Abstract read
In one paragraph

Article in Infection, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Long Xie *Clinical and Translational Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne, UK.
Xiao-Ya Zhu *State Key Laboratory of Virology, School of Life Sciences, Wuhan University, Wuhan, China.
Li Xu *Research Institute, DAAN Gene Co., Ltd., Guangzhou, China.
Xiao-Xie XuResearch Institute, DAAN Gene Co., Ltd., Guangzhou, China.
Ze-Fan RuanResearch Institute, DAAN Gene Co., Ltd., Guangzhou, China.
Ming-Xiang HuangFuzhou Pulmonary Hospital and Fujian Medical University Clinical Teaching Hospital, Fuzhou, China. hmg119@163.com.
Li ChenChaoshan Hospital, The First Affiliated Hospital of Jinan University, Chaozhou, China. 326209276@qq.com.
Xi-Wen JiangResearch Institute, DAAN Gene Co., Ltd., Guangzhou, China. yuanyecat@vip.sina.com.

Funding

Guangdong Provincial Department of Science and Technology 2022B1111020003Guangzhou Municipal Bureau of Science and Technology 202102010053
6 · The paper itself

Abstract

backgroundEscalating cases of multidrug-resistant tuberculosis (MDR-TB) pose a major challenge to global TB control efforts, necessitating innovative diagnostics to empower decentralized detection of gene mutations associated with resistance to rifampicin (RIF) and isoniazid (INH) in Mycobacterium tuberculosis (M. tuberculosis) in resource-constrained settings.

methodsCombining multiplex fluorescent PCR and Multiple Probes Melting Analysis, we identified mutations in the rpoB, katG, ahpC and inhA genes from sputum specimens. We first constructed a reference plasmid library comprising 40 prevalent mutations in the target genes' resistance determining regions and promoters, serving as positive controls. Our assay utilizes a four-tube asymmetric PCR method with specifically designed molecular beacon probes, enabling simultaneous detection of all 40 mutations. We evaluated the assay's effectiveness using DNA isolated from 50 clinically confirmed M. tuberculosis sputum specimens, comparing our results with those obtained from Sanger sequencing and retrospective validation involving bacteriological culture and phenotypic drug susceptibility testing (pDST). We also included the commercial Xpert MTB/RIF assay for accuracy comparison.

resultsOur data demonstrated remarkable sensitivity in detecting resistance to RIF and INH, achieving values of 93.33% and 95.24%, respectively, with a specificity of 100%. The concordance between our assay and pDST was 98.00%. Furthermore, the accuracy of our assay was comparable to both Sanger sequencing and the Xpert assay. Importantly, our assay boasts a 4.2-h turnaround time and costs only $10 per test, making it an optimal choice for peripheral healthcare settings.

conclusionThese findings highlight our assay's potential as a promising tool for rapidly, accurately, and affordably detecting MDR-TB.

Indexed as

Antitubercular AgentsIsoniazidMultiplex Polymerase Chain ReactionMycobacterium tuberculosisRifampinSputumTuberculosis, Multidrug-ResistantDrug Resistance, BacterialHumansMicrobial Sensitivity TestsMutationSensitivity and SpecificityAntitubercular AgentsIsoniazidRifampinMultiple probes melting analysisMultiplex fluorescence PCRMycobacterium tuberculosisRifampicin and isoniazid resistanceSputum detection

Identifiers

PMID38884858
PMCPMC11621165

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.